PeterTScardinoMDFACS

David H. Koch Chair, Attending Urologist, Dept. of Surgery

Dr. Scardino is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Memorial Sloan Kettering Cancer Center
Kimmel Center for Prostate and Urologic Cancer, 353 E. 68th St
New York, NY 10065
Phone+1 646-422-4329

Fax+1 646-422-1095

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Urology, 1979
Clinical Center at the National Institutes of HealthFellowship, Complex General Surgical Oncology, 1976
Massachusetts General HospitalResidency, Surgery, 1971 - 1973
Duke University School of MedicineClass of 1971

PubMed

2847 citations
Integrative genomic profiling of human prostate cancer
Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, Yonghong Xiao
Cancer Cell. 2010-07-13
927 citations
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver, Caren Chapinski, John Wongvipat, Haley Hieronymus, Yu Chen
Cancer Cell. 2011-05-17
2101 citations
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse, Jaeil Ahn, Rehan Akbani, Adrian Ally, Samirkumar B. Amin
Cell. 2015-11-05

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-S...
John P Mulhall, Eric A Klein, Kevin Slawin, Peter T Scardino, The Journal of Sexual Medicine

Tumor Copy Number Alteration Burden Is a Pan-Cancer Prognostic Factor Associated with Recurrence and DeathSeptember 2018
Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer as Candidates for Active Surveillance☆April 2018
Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer as Candidates for Active Surveillance☆April 2018

Focal Therapy for Prostate Cancer: Should It Become a Standard of Care?June 24th, 2022
EDAP Hosting Key Opinion Leader Call on Focal One® and ExactVu™September 15th, 2020
20-Year Follow-up Data Are in: Prostate Cancer Prevention Works; Concerns About High-Grade Disease DismissedFebruary 1st, 2019
Join now to see all

Urologic Oncology Research Training GrantNational Cancer Institute2005–2011
Developmental Research ProgramNational Cancer Institute2006–2010
Career Development ProgramNational Cancer Institute2006–2010
Spore In Prostate CancerNational Cancer Institute2001–2008
Urology Oncology Research Training GrantNational Cancer Institute1999–2003
Antenoviral Vector Delivery Of HSK TK Gene With Gancivlovir In Prostate CancerNational Center For Research Resources1998–2001
Markers Of Progression And MetastasesNational Cancer Institute1996–2001
Prostate Neoplasm--Developmental ProjectsNational Cancer Institute1992–2001
Prostate Neoplasm--Career Development ProgramNational Cancer Institute1992–2001
Spore In Prostate CancerNational Cancer Institute1996–1997
Specialized PGM Of Research Excellence/Prostate CancerNational Cancer Institute1992–1995
DNA Ploidy And Molecular Markers Of Prostate CancerNational Cancer Institute1992–1995
Transrectal Ultrasonography For Prostate CancerNational Cancer Institute1988–1992
Chemotherapy Trials For Carcinoma Of The ProstateNational Cancer Institute1985